Tsui-Fen Chou, PhD

*Curriculum Vitae*

Division of Biology and Biological Engineering E-mail: tfchou@caltech.edu

California Institute of Technology Phone: (626) 395-6772 (Office)

1200 E. California Blvd (626) 395-8392 (Lab)

MC156-29 (612) 703-4750 (Cell)

Pasadena, CA91125 https://tfchoulab.caltech.edu

**EDUCATION**

1995 – June 1999 B.S. in Pharmacy, School of Pharmacy, National Taiwan University, Taipei, Taiwan

2001 – July 2006 Ph.D. in Medicinal Chemistry, University of Minnesota, Twin Cities, USA

**Professional experience**

**Present Positions**

2019 - Research Professor, Biology and Biological Engineering, California Institute of Technology, Pasadena, CA

**Previous Positions**

1999 - 2001 Teaching Assistant, School of Pharmacy, National Taiwan University, Taipei, Taiwan

2001 - 2003 Teaching Assistant, Medicinal Chemistry, University of Minnesota, Twin Cities, MN

2006 - 2007 Postdoctoral Associate, Medicinal Chemistry, University of Minnesota, Twin Cities, MN

2007 - 2012 Postdoctoral Fellow, Biology, California Institute of Technology, Pasadena, CA

2012 - 2019 Assistant Professor (in-residence series), David Geffen School of Medicine at UCLA, CA

2019 - 2019 Associate Professor (in-residence series), David Geffen School of Medicine at UCLA, CA

2012 – 2019 Associate Faculty, UCLA Intercampus Medical Genetics Training Program, CA

2013 - 2019 Member, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA

**PROFESSIONAL ACTIVITY**

**Professional Associations and Scholarly Societies:**

2005- present American Chemical Society, Member

2007- 2011 American Association for Cancer Research, Associate Member

2009- present American Society for Biochemistry and Molecular Biology, Member

2012- present American Association for Cancer Research, Member

2012- present American Society of Human Genetics, Member

2015- present American Society for Cell Biology, Member

2016- present Genetics Society of America, Member

**HONORS**

1996, 1997 Presidential Award (Dean’s List), National Taiwan University.

1997 Student Research Fellowship, National Science Council, Taiwan

1996 - 1999 Study Fellowship, Standard Chemical & Pharmaceutical Company, Taiwan

1999 Outstanding College Youth, National Taiwan University

**AWARDS**

2004 Poster Award: The 17th International Roundtable on Nucleosides, Nucleotides and Nucleic
 Acids. Minneapolis, MN. Sept. 12 - 16.

2004 Poster Award: International Symposium for Chinese Medicinal Chemists, Taipei, Taiwan, Nov.
 18 – 22.

2006 ASBMB Travel Award: The Experimental Biology 2006 Meeting, San Francisco, April 1 - 5.

2006 ACS Travel Award: Division of Biological Chemistry, National Meeting of the American
 Chemical Society San Francisco, Sept. 10 -14.

2008 ASBMB Travel Award: The Experimental Biology 2008 Meeting, San Diego, April 5 – 9.

2012 Ubiquitin Drug Discovery and Diagnostics Conference Travel Award, Philadelphia, Aug. 24 **-** 25.

2011 Aspen Cancer Conference Fellowship Award, Aspen, July 10 – 12.

2017 LA BioMed/Liu Young Investigator Award for 2017

**RESEARCH GRANTS AND FELLOWSHIP RECEIVED**

2013 SAIC-F HHSN261200800001E (T-F Chou) NIH NEXT Request for Proposal Number S13-206. “Identify small molecule inhibitors of VCP/p97”; Leidos Biomedical Research, Inc.; 08/31/2013 – 12/31/2017; Role: PI

2016 5R41NS089061-02 (PI: S. Ekins, Consortium PI: P. Dickson) “Development and Validation
 of Enzyme Replacement Therapy for MPS III” Phoenix Nest, Inc. NIH/NINDS

 05/15/2016 – 09/29/2018; Role: Co-Investigator

2016 1R01HD086596-01A1 (P. Sternberg, T-F Chou) “Cell adhesion mediated by LINKIN”

 NIH/NICHD. 09/20/2016 - 08/31/2021; Role: PI on multiple PI project

 The goals of this project are to study the function of LINKIN in cell adhesion and
 elucidate the functional role of molecular circuits that control LINKIN functions.

2017 1R01NS100815-01 (T-F Chou) “Using HTS to Identify Inhibitors of R155H-p97/VCP
 Mutant to treat IBMPFD/ALS” NIH/NINDS. 04/01/2017 – 02/29/2020; Role: PI

 The major goals of this project are to carry out HTS screen to identify p97 small molecule
 inhibitors against R155H p97 disease mutants and develop mutant-specific inhibitors to treat
 IBMPFD/ALS.

2018 SAIC-F HHSN261200800001E (T-F Chou) NIH NEXT Agreement No. 18X001. “Identify
 small molecule inhibitors of VCP/p97”; Leidos Biomedical Research, Inc.
 01/01/2018 – 08/30/2019; Role: PI

 This project is carried out in conjunction with the p97 project team to develop p97 inhibitors.

2018 1R01NS102279 (T-F Chou) “Dysregulation of p97/VCP disease mutants in IBM and

 FTLD-U” NIH/NINDS. 07/01/2018 – 04/30/2023; Role: PI

 This project aims to identify p97 cofactors specifically relevant in disease cells that exhibit
 IBMPFD/ALS pathology and then characterize and manipulate the pathogenic dysregulation
 resulting from the R155H mutations.

2018 2U44NS089061-04 (J. Wood, C. Glass, P. Dickson, T-F Chou) “Development and Validation
 of Enzyme Replacement Therapy for MPS III” Phoenix Nest, Inc. NIH/NINDS

 The major goals of this project are to perform an in vivo efficacy study and develop a production
 process that can enable scale-up for pre-IND studies for MPS III.

2019 NIH/NCI Contract No. 75N91019D00024, Task Order No. 75N091019F00129, Subcontract No.
 20X022 (PI: Chou) “Identify small molecule inhibitors of VCP/p9711/01/2019 – 11/30/2021

|  |  |
| --- | --- |
| 2020 Merkin seed grant (PI: Chou) "Targeting the host protein p97/VCP ATPase as antiviral therapy"  05/20/20 – 11/20/2020.2021 Amylyx (PI: Chou) Title: Evaluation of Amylyx drug combination in treating P97 disease mutant  motor neuron 2021 Cleave Therapeutic (PI: Chou) Title: A Phase 1 Study to Evaluate the Safety and  Pharmacokinetic Profiles of CB-5339 (“Study Drug”) in Participants with Relapsed/Refractory  Acute Myeloid Leukemia or Intermediate- or High-Risk Myelodysplastic Syndrome.2022 Merkin seed grant (PI: Stoltz, Chou) Title: The identification of protein targets of dimeric indole  alkaloids as potential anti-cancer agents2022 J. Yang & Family Foundation (PI: Chou) Title: Support for Research Collaborations with  Taiwanese Scholars: Uncovering the biochemical and structural basis of the VDAC-p97  interaction2022 R03 TR003353 (PI: Prober, Chou) Title: Phosphoproteomic Analyses of Understudied Protein  Kinases that Affect Zebrafish Sleep. 07/07/2022 – 06/31/202232022 National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024,  Task Order No. 75N91020F00003. Chou (PI) 09/01/2022 – 08/31/202282023 Amgen Chem-Bio-Engineering Award (CBEA) (PI: Chou) Title: Identification of Blood-Brain  Barrier Penetration Mechanisms via Microorganism Models Coupled to Quantitative Targeted  Proteomics 01/01/2023 – 12/31/20223 2023 Amgen Chem-Bio-Engineering Award (CBEA) (PI: Lois; Chou) Title: Identification of  Endothelial Mechanosensing Proteins Induced by Turbulent Blood Flow in the Circulatory  System 01/01/2023 – 12/31/20223 2023 Merkin translational research grant (PI: Shan, Chou) Title: Tailor-made Molecular Chaperones to  target protein misfolding diseases.2023 Merkin translational research grant (PI: Chou) Title: Development of MitoTAC compounds to  treat Parkinson’s disease. |   |
|  |  |

**PATENTS**

1. Provisional 63/307,549 Title: Discovery of Novel Small-Molecule Inhibitors Against RUVBL1/2

 Complex Filed: 2/7/2022

2. PCT/US2022/034955; Title: Methods and Compositions For Inhibiting P97

 Filed: 6/24/2022

3. Nonprovisional 17/849,132; Title: Methods and Compositions for Inhibiting Coronaviral Replication

 Filed: 6/24/2022

4. Provisional 63/357,488; Title: NMS-873 Leads to Dysfunctional Glycometabolism by Targeting

 NDUFAF5 in a p97-Independent Manner and is Synergistic with 2-DG

 Filed: 6/30/2022

5.Nonprovisional 63/276,905; Title: Temporal Proteomics Reveal Specific Cell Cycle Oncoprotein

 Downregulation by P97/VCP Inhibition Filed: 11/08/2022

**INVITED PRESENTATIONS**

2009 High-throughput proteomic screening coupled with a chemical genetic approach to study
 p97/Cdc48. The Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan. 07/17/09

2010 High-throughput proteomic screening coupled with chemical genetic approach to study
 p97/Cdc48. School of Chemical Biology and Pharmaceutical Sciences,Capital Medical
 University, Beijing, P.R. China.02/19/10

2011 Quantitative assays for classification of ubiquitin-proteasome drugs reveal a selective inhibitor
 of p97 ATPase.” 1st Annual Ubiquitin Research and Drug Discovery Conference, San Diego,
 01/17/11

2011Using Chemical Biology to Develop Cancer Therapeutics Targeting the Ubiquitin System. Tulane University, New Orleans, Louisiana, USA, 10/31/11

2011Using Chemical Biology to Develop Cancer Therapeutics Targeting the Ubiquitin System. Harbor-UCLA Medical Center, Torrance, California, USA, 11/16/11

2011 Using Chemical Biology to Develop Cancer Therapeutics Targeting the Ubiquitin System.

 St. Jude Children’s Research Hospital, Memphis, Tennessee, USA, 12/01/11

2011 Using Chemical Biology to Develop Cancer Therapeutics Targeting the Ubiquitin System

 National Taiwan University, Taipei, Taiwan 01/31/12

2013 Targeting both the UPS and Autophagy with p97 ATPase Inhibitors to Impair Cancer Growth.
 3rd Ubiquitin Research and Drug Discovery GTC Conference, Las Vegas, 02/26/13

2015 Using p97 ATPase inhibitors to develop therapeutics targeting the ubiquitin and autophagy
 systems. University of Arizona, Tucson, Arizona, USA, 09/29/15

# 2017 Targeting p97/VCP AAA ATPase in cancer and neurodegenerative diseases. International  Conference of Cancer & Aging, Huazhong University of Science and Technology, Wuhan,  China, 10/24/17.

# 2017 Targeting p97/VCP AAA ATPase in cancer and neurodegenerative diseases. Tongji University,  Shanghai, China, 11/01/17.

2018 Developing iPSC-derived cellular assays of R155H p97/VCP to assess treatment of a rare
 degenerative disorder, LA BioMed Science Retreat, HIPO Symposium, Los Angeles, USA,
 05/18/2018.

2018 Targeting both the UPS and Autophagy with p97 ATPase Inhibitors to Impair Cancer Growth ,
 LA BioMed Science Retreat, Block Symposium, Los Angeles, USA, 05/19/2018.

2018 Targeting both the UPS and Autophagy with p97 ATPase Inhibitors to Impair Cancer Growth ,
 LA BioMed Science Retreat, Block Symposium, Los Angeles, USA, 05/19/2018.

2018 Targeting p97/VCP AAA ATPase in cancer and neurodegenerative diseases, School of Chemical
 Biology and Pharmaceutical Sciences,Capital Medical University, Beijing, P.R. China.10/19/18

# 2018 Enzyme Replacement Therapy for Mucopolysaccharidosis IIID, International  Conference of Cancer & Aging, Huazhong University of Science and Technology, Wuhan,  China, 10/26/18.

2018 Enzyme Replacement Therapy for Mucopolysaccharidosis IIID, GC Pharma, Korea, 11/12/2018

2019 Chemical Biology Approach to Rae Disease and Cancer, Washington University School of
 Medicine, St. Louis, USA, 01/31/2019

2019 Chemical Biology Approach to Rare Disease and Cancer, IMB, Academia Sinica, Taipei,
 Taiwan, 02/21/2019

2022 Chemical Biology and Proteomic Approaches to Rare Disease and Cancer, University of

 Michigan, Ann Arbor, 03/18/2022

**RESEARCH PAPERS - PEER REVIEWED**

1. Kim, J., **Chou, T.-F**., Griesgraber, G. W., and Wagner, C. R. “Direct measurement of nucleoside
 monophosphate delivery from a phosphoramidate pronucleotide by stable isotope labeling and LC-
 ESI-MS/MS.” *Molecular Pharmaceutics* **2004**, 1, 102 - 111.

2. **Chou, T.-F**., Bieganowski, P., Shilinski, K., Cheng, J., Brenner, C., and Wagner, C. R. “31P-NMR and genetic analysis establish hinT as the only *Escherichia coli* purine nucleoside phosphoramidase and as essential for growth under high salt conditions.” *J. Biol. Chem.* **2005**, 280, 15356 - 15361.

3. Carlson, J. C. T., Jena, S. S., Flenniken, F., **Chou, T.-F.,** Siegel, R. A., and Wagner, C. R. “Chemically controlled self-assembly of protein nanorings.” *J. Am. Chem. Soc.* **2006**, 128, 7630 - 7638.

4. **Chou, T.-F.**, and Wagner, C. R. “Lysyl-tRNA synthetase generated lysyl-adenylate is a
 substrate for histidine triad nucleotide binding proteins (Hints).” *J. Biol. Chem*. **2007**, 282,
 4719 - 4727.

5. **Chou, T.-F.**, Baraniak, J., Kaczmarek, R.,Zhou, X., Cheng, J., Ghosh, B., and Wagner, C.
 R. “Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate
 specificity of human and *E. coli* histidine triad nucleotide binding proteins (Hint1).”
 *Molecular Pharmaceutics* **2007**,4, 208 - 217.

6**. Chou, T.-F.**, Tikh, I. B., Horta, B.A.C., Ghosh, B., de Alencastro, R.B., and Wagner, C. R.
 “Engineered monomeric human histidine triad nucleotide binding protein 1 hydrolyzes
 fluorogenic acyl -adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate.” *J. Biol.
 Chem.* **2007,** 282, 15137 - 15147.

7. **Chou, T.-F**., Cheng, J, Tikh, I. B., and Wagner, C. R. “Evidence that human histidine triad
 nucleotide binding protein 3 (Hint3) is a distinct branch of the histidine triad (HIT)
 superfamily.” *J. Mol. Biol.* **2007**,373, 978 - 989.

8. **Chou, T.-F.**, Sham, Y. Y., and Wagner, C. R. “The Impact of the C-terminal loop of
 histidine triad nucleotide binding protein1 (Hint1) on substrate specificity.” *Biochemistry*,
 **2007**, 46, 13074 - 13079.

9. Ghosh, P., Chen, J., **Chou, T.-F.**, Jia, Y., Avdulov, S., Bitterman, P. B., Polunovsky, V. A.,
 and Wagner, C.R. “Expression, purification and characterization of recombinant mouse
 initiation factor eIF-4E as a dihydrofolate reductase (DHFR) fusion protein”. *Protein
 Expression and Purification* **2008,** 60, 132 - 139.

10. **Chou, T.-F.**, So, C., White, B.R., Carlson, J.C.T., Sarikaya, M., and Wagner, C.R.
 “Enzyme nanorings” *ACS Nano* **2008**, 2, 2519 - 2525.

11. Cheng J, Zhou X, **Chou T.-F**, Ghosh B, Liu B, Wagner CR. “Identification of the amino
 acid-AZT-phosphoramidase by affinity T7 phage display selection. *Bioorg. Med. Chem.
 Lett.* **2009**, 19, 6379 - 6381.

12. Bardaweel, S., Pace, J., **Chou, T.-F**., Cody, V., and Wagner, C.R. “Probing the impact of
 the *ec*hinT c-terminal domain on structure and catalysis.” *J. Mol. Biol*. **2010,** 404, 627 - 638.

13. **Chou, T.-F.\***, and Deshaies, R. J\*. “Quantitative cell-based protein degradation assays to
 identify and classify drugs that target the ubiquitin-proteasome system. *J. Biol. Chem.* **2011**,
 286, 16546 - 16554. \***Co-corresponding authors**

14. **Chou, T.-F.\*,** Brown, S. J., Minond, D., Nordin, B.E., Li, K., Jones, A.C., Chase, P.,
 Porubsky, P. R., Stoltz, B.M., Schoenen, F. J., Patricelli, M.P., Hodder, P., Rosen, H., and
 Deshaies, R. J\*. “Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and
 autophagic protein clearance pathways” *Proc. Natl. Acad. Sci. USA.* **2011,** 108, 4834 -
 4839. \***Co-corresponding authors**

15. Birkus, G., Kutty, N.,Frey, C.R., Shribata, R. **Chou, T.-F.**, Wagner, C.R., McDermott, M.,
 and Cihlar, T. “Role of cathepsin A and lysosomes in the intracellular activation of novel
 anti-papillomavirus agent GS-9191. *Antimicrob. Agents Chemother*. **2011**, 55, 2166 - 2173.

16. **Chou, T.-F\*.**, and Deshaies, R. J\*. “Development of p97 AAA ATPase inhibitors.
 *Autophagy.* **2011**, 7, 1091-1092. \***Co-corresponding authors**

17. Bardaweel, S., Ghosh, B., **Chou, T.-F.**, Sadowsky, M.J., and Wagner, C.R. “*E. coli*
 histidine triad nucleotide binding protein 1 (ecHinT) is a catalytic regulator of D-alanine
 dehydrogenase (DadA) activity in vivo. *PLoS One*. **2011**, 6, e20897.

18. **Chou, T.-F**\*., Li, K., Frankowski, K., Schoenen, F. J., and Deshaies, R. J\*. “Structure-
 Activity Relationship study reveals ML240 and ML241 as potent and selective inhibitors of
 p97 ATPase” *ChemMedChem.* **2013**, 8,297-312. \***Co-corresponding authors**

19. Zhou, X., **Chou, T.-F**, Aubol, B.E., Park, C. J.,Wolfenden, R., Adams, J. and Wagner, C.R.
 “Kinetic Mechanism of Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) ”
 *Biochemistry*, **2013**, 52, 3588-3600

20**. Chou, T.-F\***, Bulfer, S. L., Weihl, C.C., Li, K., Lis, L. G., Walters, M. A., Schoenen, F.
 J., Lin, H. J., Deshaies, R. J, and Arkin, M. R. “Specific Inhibition of p97/VCP ATPase and
 Kinetic Analysis Demonstrate Interaction between D1 and D2 ATPase domains” *J. Mol. Biol.*
 **2014**, 426, 2886-2899. \***Corresponding author**

21.Gonzalez, M.A., Feely, S., Speziani, F., Strickland, A., Danzi, M., Bacon, C., Youjin Lee, Y.,
 **Chou, T.-F**, Blanton, S.H., Weihl, C.C., Zuchner, S., Shy, M. “A Novel Mutation in VCP Causes
 Charcot-Marie-Tooth Type 2 Disease” *Brain*, **2014**, PMID: 25125609.

22. Sapir, A., Tsur, A., Koorman, T., Ching, K., Bardenheier, A., Podolsky, L., Bening-Abu-Shach, U.,
 Boxem, M., **Chou, T.-F**, Broday, L., and Sternberg, P.W. “Controlled sumoylation of the
 mevalonate pathway enzyme HMGS-1 regulates metabolism during aging” *Proc. Natl.
 Acad. Sci. USA.* **2014,**111, E3880-3889.

23.Kato, M., **Chou, T.-F**, Yu, C.Z., Demodena, J., and Sternberg, P.W. “LINKIN, a new
 transmembrane protein necessary for cell adhesion” *eLife*. **2014,** e04449. (PMID:25437307)

24. Fang, C., Gui, L., Zhang, X., Moen, D.R., Li, K., Frankowski, K. J., Lin, H.J., Schoene, F.J., and
 **Chou, T.-F** “Evaluating p97 inhibitor analogues for their domain-selectivity and potency against
 the p97-p47 complex” *ChemMedChem,* **2015,** 10, 52-56. (PMID: 25377500)

25. Weihl, C. C., Baloh, R. H., Lee, Y., **Chou, T.-F**, Pittman, S. K., Lopate, G., Allred, P., Jockel-
 Balsarotti, J., Pestronk , A., and Harms, M. B. “Targeted sequencing and identification of genetic
 variants in sporadic inclusion body myositis. *Neuromuscul Disord*., **2015** Apr;25(4):289-296.

26. Zhang, X., Gui, L., Zhang, X., Bulfer, S. L., Sanghez, V., Wong, D., Lee, Y.J., Lehmann, L., Lee,
 J. S., Shih, P.-Y., Lin, H. J., Iacovino, M., Weihl, C. C., Arkin, M. R., Wang, T., **Chou, T.-F**.
 “Altered cofactor regulation with disease associated p97/VCP mutations.” *Proc. Natl. Acad.
 Sci. USA*, **2015**, 112, E1705-1714.

27. Jerath, N.U., Crockett, C.D., Moore, S.A., Shy, M.E., Weihl, C.C, **Chou, T.-F**,
 Gonzalez, M.A., Zuckner, S., and Swenson A. “Rare Manifestation of a c.290 C>T, p.Gly97Glu
 VCP Mutation.” *Case Rep Genet*. **2015**; 2015:239167.

28. Liu, M., Lin, L., Gebremariam, T., Luo, G., Skory, C. D., French, S. W., **Chou, T.-F**,, Edwards, J.
 E., Jr., and Ibrahim, A. S. (2015) “Fob1 and Fob2 Proteins Are Virulence Determinants of
 *Rhizopus oryzae* via Facilitating Iron Uptake from Ferrioxamine.” *PLoS Pathog.* **2015,** 11, e1004842

29. Klionsky, D.J. et al., Guidelines for the use and interpretation of assays for monitoring autophagy
 (3rd edition). *Autophagy.* 2016, 12, 1-222.

30.Gui, L , Zhang, X, Li, K., Frankowski, K., Li, S., Wong, D., Moen, D.R, Porubsky, P.R.,
 Lin, H. J., Schoene, F.J., **Chou, T.-F. “**Evaluating p97 Inhibitor Analogues for Potency against
 p97-p37 and p97-Npl4-Ufd1 Complexes*.” ChemMedChem*, **2016,** 11, 953-957.

31. Bulfer, S. L., **Chou, T.-F.**, Arkin, M. R. “p97 disease mutations modulate nucleotide-
 induced conformation to alter protein-protein interactions” *ACS Chem Biol.* **2016,** 11, 2112-2116.

# 32. Perez C., Li J., Parlati F., Rouffet M., Ma Y., Mackinnon A.L., **Chou, T.-F**., Deshaies R. J., Cohen  S. M. “Discovery of an Inhibitor of the Proteasome Subunit Rpn11.” J. Med. Chem. **2017**, 60,  1343-1361.

33. Segura-Cabrera, A., Tripathi, R., Zhang, X, Gui, L , **Chou, T.-F**, Komurov, K. “A structure- and
 chemical genomics-based approach for repositioning of drugs against VCP/p97 ATPase “
 *Scientific Reports* **2017**, 7,44912

34. Lee, Y.J **Chou, T.-F**, Pittman, S.K., Weihl, C. C. “Keap1/Cullin3 Modulates p62/SQSTM1
 Activity via UBA domain Ubiquitination” *Cell Reports* **2017**, 19, 188-202.

35. Shah, R#, **Chou, T.-F #,** Maize, K. M, , Strom, A., Finzel, B. C. and Wagner, C. R. ” Inhibition by
 Divalent Metal Ions of Human Histidine Triad Nucleotide Binding Protein1 (hHint1), a Regulator
 of Opioid Analgesia and Neuropathic Pain” *Biochemical and Biophysical Research
 Communications (BBRC)* **2017**, 491,760-766 # Both authors contributed equally.

36. Bastola, P., Wang, F., Schaich, M.A., Gan, T., Freudenthal, B.E., **Chou, T.-F**, Chien, J., “Specific
 mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance
 to VCP inhibitors” *Cell Death Discovery* **2017**, e17065.

37. Sanghez, V., Luzzi, A., Clarke, D., Kee, D., Buder, S., Rux, D., Osawa, M., Madrenas, J.,
 **Chou, T.-F**., Kyba, M., Iacovino, M. “Notch activation is required for downregulation of HoxA3-
 dependent endothelial cell phenotype during blood formation.”*PLoS One*, **2017**, 12, e0186818.

# 38. Nakasone, M.A., Lewis, T.A., Walker, O., [Thakur, A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Thakur%20A%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Mansour, W](https://www.ncbi.nlm.nih.gov/pubmed/?term=Mansour%20W%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Castañeda, C.A](https://www.ncbi.nlm.nih.gov/pubmed/?term=Casta%C3%B1eda%20CA%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Goeckeler- Fried, J.L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Goeckeler-Fried%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Parlati, F](https://www.ncbi.nlm.nih.gov/pubmed/?term=Parlati%20F%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., **Chou, T.-F**., [Hayat, O](https://www.ncbi.nlm.nih.gov/pubmed/?term=Hayat%20O%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Zhang, D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Zhang%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Camara, C.M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Camara%20CM%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Bonn, S.M](https://www.ncbi.nlm.nih.gov/pubmed/?term=Bonn%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Nowicka,  U.K](https://www.ncbi.nlm.nih.gov/pubmed/?term=Nowicka%20UK%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Krueger, S](https://www.ncbi.nlm.nih.gov/pubmed/?term=Krueger%20S%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Glickman, M.H](https://www.ncbi.nlm.nih.gov/pubmed/?term=Glickman%20MH%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Brodsky, J.L](https://www.ncbi.nlm.nih.gov/pubmed/?term=Brodsky%20JL%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Deshaies, R.J](https://www.ncbi.nlm.nih.gov/pubmed/?term=Deshaies%20RJ%5BAuthor%5D&cauthor=true&cauthor_uid=29153505)., [Fushman, D](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fushman%20D%5BAuthor%5D&cauthor=true&cauthor_uid=29153505). “ Structural Basis  for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.” Structure. **2017**,  25,1839-1855.

39. Sanghez, V., Chen, M., Li, S., **Chou, T.-F.**, Iacovino, M., Lin, H. J., Lasky, J. L., and Panosyan, E.
 H., “Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against
 Glioma Cells and Intracranial Mouse Medulloblastoma.” *Anticancer Research*, 2018, 38, 2627-
 2634.

40. Li J, Zhang Y, Da Silva Sil Dos Santos B, Wang F, Ma Y, Perez C, Yang Y, Peng J, Cohen SM,
 **Chou, T.-F**, Hilton ST, Deshaies RJ. “Epidithiodiketopiperazines Inhibit Protein Degradation by
 Targeting Proteasome Deubiquitinase Rpn11.” *Cell Chem Biol*. 2018; S2451-
 9456(18)30264-2.

41. LaPorte MG, Burnett JC, Colombo R, Bulfer SL, Alverez C, **Chou, T.-F**, Neitz RJ, Green N,
 Moore WJ, Yue Z, Li S, Arkin MR, Wipf P, Huryn DM.” Optimization of Phenyl Indole Inhibitors
 of the AAA+ ATPase p97. *ACS Med Chem Lett*. 2018, 9(11):1075-1081

42. Findlay, A. R, Bengoechea, R., Pittman, S. K., **Chou, T.-F**, Heather L True, H. L., and Weihl, C.
 C.” Lithium chloride corrects weakness and myopathology in a preclinical model of LGMD1D”
 *Neurol Genet* 2019;5:e318.

43. Wang F, Li S, Gan T, Stott GM, Flint A, **Chou, T.-F**. “Allosteric p97 Inhibitors Can Overcome
 Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy” *ChemMedChem*.

  2020; 15, 685-694

**2021**

44. F. Wang, D.R. Moen, C. Sauni, S. Kan, S. Li, S.Q. Le, B. Lomenick, X. Zhang, S. Ekins, S.
 Singamsetty, J. Wood, P.I. Dickson, and **Chou, T.-F**. “Enzyme Replacement Therapy for
 Mucopolysaccharidosis IIID using Recombinant Human α-N-Acetylglucosamine-6-Sulfatase in
 Neonatal Mice.” Mol Pharm. **2021**, 18(1), 214-227.

45. Zhang, G., Li, S., Wang, F., Jones A.C., Goldberg, A.F.G, Ling, B., Virgil, S., Stoltz BM,
 Deshaies RJ, and  **Chou, T.-F.** “A covalent p97/VCP ATPase inhibitor can overcome resistance to
 CB-5083 and NMS-873 in colorectal cancer cells.“ *Eur. J. Med. Chem.* 2021, 231, 113148.

46. G. Zhang, S. Li, K.W. Cheng, and **Chou, T.-F.** “AAA ATPases as Therapeutic Targets: Structure,
 Function, and Small-Molecule Inhibitors.” Eur. J. Med. Chem. **2021**, 219, 113446.

47. K.W. Cheng, F. Wang, G.A. Lopez, S. Singamsetty, J. Wood, P.I. Dickson, and
 **Chou, T.- F.**  Evaluation of artificial signal peptides for secretion of two lysosomal enzymes in
 CHO cells. Biochem. J. **2021**, 478(12), 2309-2319.

48. X. Yang, X. Yang, H. Yu, L. Na, T. Ghosh, J.B. McArthur, **Chou, T.-F.** , P. Dickson, and X.
 Chen. “A GH89 human α-N-acetylglucosaminidase (hNAGLU) homologue from gut microbe
 Bacteroides thetaiotaomicron capable of hydrolyzing heparosan oligosaccharides.” AMB
 Express. **2021**, 11(1), 94.

49. D.E. Michels, B. Lomenick, **Chou, T.-F.** , M.J. Sweredoski, and A. Pasulka. Amino Acid Analog
 Induces Stress Response in Marine Synechococcus. Appl. Environ Microbiol. **2021**, 87(15),
 e0020021

50. A. Wani, J. Zhu, J.D. Ulrich, A. Eteleeb, A.D. Sauerbeck, S.J. Reitz, K. Arhzaouy, C. Ikenaga,
 C.M. Yuede, S.K. Pittman, F. Wang, S. Li, B.A. Benitez, C. Cruchaga, T.T. Kummer, O. Harari,
 **Chou, T.-F.**, R. Schröder, C.S. Clemen, and C.C. Weihl. Neuronal VCP loss of function
 recapitulates FTLD-TDP pathology. Cell Rep. **2021**, 36(3), 109399.

51. P. Nandi, S. Li, R.C.A. Columbres, F. Wang, D.R. Williams, Y.P. Poh, **Chou, T.-F.** , and P.L.
 Chiu. Structural and Functional Analysis of Disease-Linked p97 ATPase Mutant Complexes. Int. J.
 Mol. Sci. **2021**, 22(15), 8079.

52. Zhang, X., Gui, L., Li, S., Nandi, P., Columbres, R.C., Wong, D.E., Moen, D.R., Lin, H.J., Chiu,
 P.L., and **Chou, T.-F.** “Conserved L464 in p97 D1-D2 linker is critical for p97 cofactor regulated
 ATPase activity*.” Biochem J.* 2021, 478, 3185-3204.

53. Q.T. Phan, J. Lin, N.V. Solis, M. Eng, M. Swidergall, F. Wang, S. Li, S.L. Gaffen, **Chou, T.-F.**,
 and S.G. Filler. The Globular C1q Receptor Is Required for Epidermal Growth Factor Receptor
 Signaling during Candida albicans Infection. mBio, **2021**, e0271621.

54. Cheng, K.-W, Li, S., Wang, F., Ruiz-Lopez, N.M., Hourebi, N., and **Chou, T.-F.** “ Impacts of p97
 on proteome changes in human cells during coronaviral replication.**“** *Cells*, **2021**, 10, 2953.

**2022**

55. Wang, F., Li, S., Hourebi, N., and **Chou, T.-F. “** Temporal proteomics reveal specific cell cycle
 oncoprotein downregulation by p97/VCP inhibition” *Cell Chem. Biol*. **2022**,29, 517-529.

56. Wang F., Li S., Cheng K.W., Rosencrans W.M., **Chou, T.F.** The p97 Inhibitor UPCDC-30245
 Blocks Endo-Lysosomal Degradation. *Pharmaceuticals (Basel).* 2022 Feb 7;15(2):204. doi:
 10.3390/ph15020204.

57. Li S, Wang F, Zhang G, **Chou, T.-F**. NMS-873 Leads to Dysfunctional Glycometabolism in A

 p97-Independent Manner in HCT116 Colon Cancer Cells. *Pharmaceutics.* 2022 Mar 31;14(4). doi:

 10.3390/pharmaceutics14040764.  PMID: 35456598; PMC9024726.

58. Wang F, Li S, Rosencrans WM, Cheng KW, Stott GM, Mroczkowski B, **Chou, T.-F**. Sulforaphane

 is Synergistic with CB-5083 and Inhibits Colony Formation of CB-5083-Resistant HCT116 Cells.

 *ChemMedChem*. 2022 Jun 3;17(11):e202200030. doi: 10.1002/cmdc.202200030.

59. Zhang G, Wang F, Li, S., Cheng, K.W., Cheng, Zhu, Y., Huo, R., Abdukirim, E., Kang, G.
 and **Chou, T.-F. “**Discovery of small-molecule inhibitors of RUVBL1/2 ATPase. *Bioorg Med
 Chem.* 2022, 62, 116726.

60. Wang F, Li S, Wang TY, Lopez GA, Antoshechkin I, **Chou, T.-F**.  p97/VCP ATPase inhibitors

 can rescue p97 mutation-linked motor neuron degeneration. *Brain Commun*. 2022, 4,
 fcac176.  PMC9294923.

61. Ravanfar R, Sheng Y, Shahgholi M, Lomenick B, Jones J, **Chou, T.-F**., Gray HB, Winkler JR.

 Surface cysteines could protect the SARS-CoV-2 main protease from oxidative damage. *J Inorg*

 *Biochem*. 2022, 234, 111886. PMC9161685.

62. LeBlanc AK, Mazcko CN, Fan TM, Vail DM, Flesner BK, Bryan JN, Li S, Wang F, Harris S,

 Vargas JD, Govindharajulu JP, Jaganathan S, Tomaino F, Srivastava AK, **Chou, T.-F**., Stott GM,

 Covey JM, Mroczkowski B, Doroshow JH. Comparative Oncology Assessment of a Novel

 Inhibitor of Valosin-Containing Protein in Tumor-Bearing Dogs. *Mol Cancer Ther*. 2022

 ,21, 1510-1523. PMC9538592.

63. Yang CI, Zhu Z, Jones JJ, Lomenick B, **Chou, T.-F**., Shan SO. System-wide analyses reveal

 essential roles of N-terminal protein modification in bacterial membrane integrity. *iScience*. 2022

 25,104756. PMID: 35942092; PMCID: PMC9356101.

64. Puskar R, Du Truong C, Swain K, Chowdhury S, Chan KY, Li S, Cheng KW, Wang TY, Poh YP,

 Mazor Y, Liu H, **Chou, T.-F**., Nannenga BL, Chiu PL. Molecular asymmetry of a photosynthetic

 supercomplex from green sulfur bacteria. *Nat Commun*. 2022, 13, 5824. PMC9529944.

65. Guna A, Stevens TA, Inglis AJ, Replogle JM, Esantsi TK, Muthukumar G, Shaffer KCL, Wang

 ML, Pogson AN, Jones JJ, Lomenick B, **Chou, T.-F**., Weissman JS, Voorhees RM. MTCH2 is a

 mitochondrial outer membrane protein insertase. *Science*. 2022, 378,317-322. PMID: 36264797.

66. Spero MA, Jones J, Lomenick B, **Chou, T.-F**., Newman DK. Mechanisms of chlorate toxicity and

 resistance in Pseudomonas aeruginosa. *Mol Microbiol.* 2022 Oct;118(4):321-335. PMC9589919.

**2023**

67. Wang GZ, Warren EA, Haas AL, Peña AS, Kiedrowski MR, Lomenick B, **Chou, T.-F**, Bomberger JM, Tirrell DA, Limoli DH. Staphylococcal secreted cytotoxins are competition sensing signals for Pseudomonas aeruginosa. bioRxiv [Preprint]. 2023 Jan 29:2023.01.29.526047. doi: 10.1101/2023.01.29.526047. PMID: 36747623; PMCID: PMC9900984.

68. Tan CH, Cheng KW, Park H, Sternberg PW, **Chou, T.-F**. LINKIN-associated proteins necessary for tissue integrity during collective cell migration. bioRxiv [Preprint]. 2023 Feb 9:2023.02.08.527750. doi: 10.1101/2023.02.08.527750. PMID: 36798316; PMCID: PMC9934607.

69. Le Guerroué F, Bunker EN, Rosencrans WM, Nguyen JT, Basar MA, Werner A, **Chou, T.-F**, Wang C, Youle RJ. TNIP1 inhibits selective autophagy via bipartite interaction with LC3/GABARAP and TAX1BP1. Mol Cell. 2023 Mar 2:S1097-2765(23)00150-8. doi: 10.1016/j.molcel.2023.02.023. Epub ahead of print. PMID: 36898370.

70. Dutka P, Metskas LA, Hurt RC, Salahshoor H, Wang TY, Malounda D, Lu GJ, **Chou, T.-F**, Shapiro MG, Jensen GJ. Structure of Anabaena flos-aquae gas vesicles revealed by cryo-ET. Structure. 2023 May 4;31(5):518-528.e6. doi: 10.1016/j.str.2023.03.011. Epub 2023 Apr 10. PMID: 37040766; PMCID: PMC10185304.

71. Jones, J., MacKrell, E. J., Wang, T. Y., Lomenick, B., Roukes, M. L., & **Chou, T.-F**, (2023). Tidyproteomics: an open-source R package and data object for quantitative proteomics post analysis and visualization. BMC bioinformatics, 24(1), 239. doi: <https://doi.org/10.1186/s12859-023-05360-7>. PMID: 37280522; PMCID: PMC10246047.

72. Findlay, A. R., Paing, M. M., Daw, J. A., Haller, M., Bengoechea, R., Pittman, S. K., Li, S., Wang, F., Miller, T. M., True, H. L., **Chou, T.-F**, & Weihl, C. C. (2023). DNAJB6 isoform specific knockdown: Therapeutic potential for limb girdle muscular dystrophy D1. Molecular therapy. Nucleic acids, 32, 937–948. doi: <https://doi.org/10.1016/j.omtn.2023.05.017>. PMID: 37346979; PMCID: PMC10280091.

73. Tu, J., Min, J., Song, Y., Xu, C., Li, J., Moore, J., Hanson, J., Hu, E., Parimon, T., Wang, T. Y., Davoodi, E., **Chou, T.-F**, Chen, P., Hsu, J. J., Rossiter, H. B., & Gao, W. (2023). A wireless patch for the monitoring of C-reactive protein in sweat. Nature biomedical engineering, 10.1038/s41551-023-01059-5. doi: <https://doi.org/10.1038/s41551-023-01059-5>. Advance online publication. PMID: 37349389

74. Gupta, A., Lu, C., Wang, F., **Chou, T.-F**., & Shan, S. O. (2023). An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesis. Protein science : a publication of the Protein Society, e4728. doi: <https://doi.org/10.1002/pro.4728>. Advance online publication. PMID: 37433015.

75. LaPorte MG, Alverez C, Chatterley A, Kovaliov M, Carder EJ, Houghton MJ, Lim C, Miller ER, Samankumara LP, Liang M, Kerrigan K, Yue Z, Li S, Tomaino F, Wang F, Green N, Stott GM, Srivastava A, **Chou, T.-F**, Wipf P, Huryn DM. Optimization of 1,2,4-Triazole-Based p97 Inhibitors for the Treatment of Cancer. ACS Med Chem Lett. 2023 Jun 21;14(7):977-985. doi: 10.1021/acsmedchemlett.3c00163. PMID: 37465292; PMCID: PMC10351062.

76. Schiava M, Ikenaga C, Topf A, Caballero-Ávila M, **Chou, T.-F**, Li S, Wang F, Daw J, Stojkovic T, Villar-Quiles R, Nishino I, Inoue M, Nishimori Y, Saito Y, Katsuno M, Noda S, Ito C, Otsuka M, Nahir S, Manousakis G, Walk D, Quinn C, Alfano L, Sahenk Z, Tasca G, Monforte M, Sabatelli M, Bisogni G, Oldfors A, Rydeliu A, Pal E, Paradas C, Velez B, De Bleecker JL, Farugia ME, Longman C, Harms MB, Ralston S, Zanoteli E, Macedo Serafim da Silva A, Sotoca J, Juntas-Morales R, Bevilacqua J, Balart M, Talbot S, Straub V, Guglieri M, Marini-Bettolo C, Diaz-Manera J, Weihl CC. Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy. Neurol Genet. 2023 Aug 15;9(5):e200093. doi: 10.1212/NXG.0000000000200093. PMID: 37588275; PMCID: PMC10427110.

77. Luzzi A, Wang F, Li S, Iacovino M, **Chou, T.-F**. Skeletal muscle cell protein dysregulation highlights the pathogenesis mechanism of myopathy-associated p97/VCP R155H mutations. Front Neurol. 2023 Aug 3;14:1211635. doi: 10.3389/fneur.2023.1211635. PMID: 37602234; PMCID: PMC10435852.

78. Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, Guo L, Cho H, Li A, Behal A, Mirzapoiazova T, Massarelli E, Koczywas M, Arvanitis LD, Walser T, Villaflor V, Hamilton S, Mambetsariev I, Sattler M, Nasser MW, Jain M, Batra SK, Soldi R, Sharma S, Fakih M, Mohanty SK, Mainan A, Wu X, Chen Y, He Y, **Chou, T.-F**., Roy S, Orban J, Kulkarni P, Salgia R. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer. Sci Adv. 2023 Oct 13;9(41):eade3816. doi: 10.1126/sciadv.ade3816. Epub 2023 Oct 13. PMID: 37831779; PMCID: PMC10575592.